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CASE REPORT
Neonatal Erythema Multiforme: A Case Report
Young Joon Cho, M.D.
1, Sun Young Huh, M.D., Jong Soo Hong, M.D., Jae Yoon Jung, M.D., 
Dae Hun Suh, M.D.
Department of Dermatology, Seoul National University College of Medicine, 
1Chois Skin Clinic, Seoul, Korea
Erythema multiforme (EM) is an extremely rare condition in 
infancy. To the best of our knowledge, there have been only 
three cases of neonatal EM described in the literature, and no 
such cases have been reported in Korea. A preterm neonate 
born at 35 weeks and six days of gestation presented with 
multiple annular erythematous patches with a targetoid 
shape over his entire body at 36 days of age (corrected age 
of 7 days). He had no systemic symptoms except for transient 
mild fever. No triggering factor except for hepatitis B and 
BCG vaccination was found. Neutropenia was noted upon 
laboratory analysis. Skin biopsy specimens showed findings 
suggestive of erythema multiforme. The skin lesions 
improved rapidly upon administration of intravenous 
methylprednisolone; however, neutropenia continued for a 
much longer period. The significance of neutropenia with 
respect to the development of EM was not clarified. There has 
been no recurrence of skin lesions over a one-year follow-up 
period. (Ann Dermatol 23(3) 382∼385, 2011)
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INTRODUCTION
Erythema multiforme (EM) is an acute, self-limited disorder 
involving the skin and mucous membranes with common 
recurrences. EM is usually divided into two forms, EM 
minor and EM major. EM minor presents skin lesions 
without involvement of mucous membranes, while EM 
major is more severe, presenting both skin and mucous 
membrane lesions
1,2.
EM affects males more often than females, with a male: 
female ratio ranging from 3:2 to 2:1. Although it can occur 
in all ages, EM usually affects adolescents and young 
adults, and rarely occurs during infancy and childhood. 
Indeed, there have been only three cases of biopsy-proven 
EM during the neonatal period in the literature
3-7. Here, 
we report a case of EM in a neonate.
CASE REPORT
A 36-day-old male preterm infant (corrected age of 7 days) 
was admitted to our hospital with complaints that skin 
lesions developed on his neck and inguinal area and then 
spread to his entire body within a day. The patient had 
been born at 35 weeks and 6 days of gestation, and had a 
birth weight of 3,150 g. The pregnancy was uncomplicat-
ed, and there was no remarkable family history or past 
medical history including infections or drug intake. The 
first dose of hepatitis B vaccination was administered after 
birth, and BCG vaccination, which is generally recom-
mended in Korea, was administered at 30 days of age.
Upon admission, the infant appeared well, with only 
low-grade pyrexia (37.5
oC) that subsided the next day. His 
entire body was covered with well-defined annular 
erythematous patches of variable size, which were typical 
targetoid shape. The center of the round erythematous 
patches was darker than the periphery (Fig. 1). However, 
the face, palms, soles and mucous membranes were 
spared. The rest of his physical examination was normal.
Laboratory evaluation showed neutropenia (total white 
blood cell [WBC] count 7.83×10
3/μl; normal 5.0∼
19.5×10
3/μl, absolute neutrophil count [ANC] 0.626× 
10
3/μl; normal 1.0∼8.5 ×10
3/μl)
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Fig. 1. (A) The entire body was co-
vered by well-defined erythematous 
patches with a targetoid shape. (B) 
Typical targetoid lesions on left leg.
Fig. 2. (A) Histologic section showing a lymphocytic infiltration in the upper dermis with papillary edema (H&E, ×200). (B) Vacuolar
change in the basal cell layer (black arrow), and necrotic keratinocytes (white arrow) within the epidermis (H&E, ×400).
smear was conducted and revealed some anisocyotisis, 
poikilocytosis and lymphocytosis. However, these were 
not considered clinically significant. Serologic findings, 
including antibodies to herpes simplex virus and surface 
hepatitis B virus antigens, were negative. A skin biopsy 
specimen obtained from his right lower leg revealed a 
lymphohistiocytic infiltration in the upper dermis with 
papillary edema. Vacuolar degeneration of the basal cell 
layer and necrotic keratinocytes within the epidermis 
were also observed (Fig. 2). These findings were 
compatible with the diagnosis of erythema multiforme.
The patient improved rapidly upon administration of 
intravenous methylprednisolone at a dose of 0.5 mg/kg/day 
for three days, followed by a tapering dose of oral methyl-YJ Cho, et al
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prednisolone over three days, and was discharged on the 
fifth day of admission. The skin lesions cleared without 
scarring within a few days; however, neutropenia per-
sisted for a month and the ANC slowly increased. The 
ANC was 1.094×10
3/μl one month later and 5.03×10
3/
μl 10 months later. At 1 year of follow up, there had 
been no recurrence or other systemic sequelae.
DISCUSSION
EM occurs commonly in adolescents and young adults. 
However, it has rarely been reported in neonates and 
infants
3,4. Moreover, to our knowledge, there have been 
only three cases of biopsy-proven EM during the neonatal 
period, and no such cases have been reported in Korea. 
The first case was demonstrated by Dikland et al.
5 in 1986 
in a 3-week-old female. The girl had no involvement of 
the mucous membranes. Congenital hepatitis was 
diagnosed, but other microbiological and serological 
studies, including herpes simplex virus (HSV), showed no 
evidence of recent infection. The skin lesions sponta-
neously disappeared within two weeks without any 
treatment. The second case was reported by Johnston et 
al.
6 in 2002 in a 25-day-old male. The patient had 
prodromal symptoms including rhinorrhea, fever, drow-
siness and anorexia, which suggested an upper respiratory 
tract infection. He developed an unusual eruption with 
bullae and marked systemic symptoms. Chest X-ray 
revealed bilateral pulmonary infiltrates late in the course 
of the disease. There was no triggering factor. Symptoms 
began to resolve spontaneously after two weeks. The third 
case was described by Torrelo et al.
7 in 2003 in a 
2-week-old boy. The patient had no triggering factor for 
EM except for hepatitis B vaccination. However, hepatitis 
B antigens were not detected in the skin biopsy. The skin 
lesions cleared without scarring two weeks after the onset 
of the disease.
There were also several reports of neonatal EM without 
skin biopsy examination
9-12. Suggested etiologic factors of 
these cases included cow’s milk protein
9, drugs
10, 
hepatitis B vaccination
11 and candida infection
12. 
In this case, the patient did not show any systemic 
symptoms except for transient mild fever. The short 
duration of fever and absence of lymphadenopathy, 
extremity changes and mucosal involvement excluded 
Kawasaki’s disease. In addition, we could not find any 
triggering factor for EM except for hepatitis B and BCG 
vaccination. Considering that EM is a reactive pheno-
menon that occurs 5∼7 days after an initial insult, BCG 
vaccination, which was administered five days before the 
onset of the disease, could have been related to 
development of the skin lesions. Dermatological compli-
cations after BCG vaccination are rarely seen; however, 
they include specific skin reactions such as lupus vulgaris, 
scrofuloderma, regional lymphadenitis or tuberculid and 
nonspecific reactions such as keloid, urticaria, granuloma 
annulare or erythema nodosum
13,14. To date, there have 
been two reports suggesting an association of EM with 
BCG vaccination as a nonspecific reaction
15,16. These 
reactions may be mediated by immunological hypersen-
sitivity reaction to antigens in the vaccine. However, the 
exact pathogenesis remains unclear.
Interestingly, neutropenia continued for a month. The 
ANC was 0.626×10
3/μl at admission, 1.094×10
3/μl 
one month later, and 5.03×10
3/μl ten months later. It has 
been reported that neonatal neutropenia occurs in 6∼8% 
of infants, and there are many potential causes of neonatal 
neutropenia ranging from life threatening disease to 
transient benign causes of little clinical significance. 
Acquired or secondary neutropenia precipitated by drugs 
or infection is usually self-limiting. The duration of neutro-
penia is variable, with about 70% of the neutropenic 
episodes lasting less than one week but cases caused by 
viral infection or of unknown origin can last longer
17-19. 
Investigations to identify the underlying infectious causes 
in the present case revealed no abnormality. There have 
been no previous studies concerning neutropenia 
associated with EM or BCG vaccination. We could not 
clarify the relationship between neutropenia and EM and 
thought that this finding indicated transient benign 
neutropenia. Although the patient had no subjective 
symptoms except for transient mild fever, and serologic 
studies revealed no evidence of infections, it might have 
been associated with a subclinical viral infection. 
Systemic corticosteroid therapy for EM is controversial 
because of conflicting reports and the lack of controlled 
studies. Some have suggested that the use of systemic 
corticosteroids could decrease the severity of the disease if 
they were administered early during the course of the 
disease, while others have reported delayed recovery time 
and increased complications
20-23.
Further studies are needed to evaluate the etiologies and 
treatment of neonatal EM, and dermatologists should pay 
attention to this rare event. 
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